Table SVI. MUC22 expression and association with clinicopathologic parameters in lung cancer patients.

| Characteristics          | No. of cases | MUC22<sup>High</sup> n (%) | MUC22<sup>Low</sup> n (%) | P-value  |
|--------------------------|--------------|-----------------------------|---------------------------|----------|
| Total                    | 993          | 311 (31.3)                  | 682 (68.7)                |          |
| Sex                      |              |                             |                           |          |
| Male                     | 593          | 143 (24.1)                  | 450 (75.9)                |          |
| Female                   | 399          | 168 (42.1)                  | 231 (57.9)                | 2.1×10<sup>-10</sup>b |
| Age (years)              |              |                             |                           |          |
| ≥60                      | 744          | 218 (29.3)                  | 526 (70.7)                |          |
| <60                      | 245          | 93 (38.0)                   | 152 (62.0)                | 0.011<sup>a</sup> |
| Pathological type        |              |                             |                           |          |
| LUAD                     | 499          | 251 (50.3)                  | 248 (49.7)                |          |
| LUSC                     | 494          | 60 (12.1)                   | 434 (87.9)                | 7×10<sup>-20</sup>b |
| Clinic stage             |              |                             |                           |          |
| I                        | 510          | 159 (31.2)                  | 351 (68.8)                |          |
| LUAD                     | 131          | 131                         |                           |          |
| LUSC                     | 28           | 28                          |                           |          |
| II                       | 279          | 85 (30.5)                   | 194 (69.5)                | 0.835    |
| LUAD                     | 64           | 54                          |                           |          |
| LUSC                     | 21           | 21                          |                           |          |
| III                      | 159          | 50 (31.4)                   | 109 (68.6)                | 0.95     |
| LUAD                     | 42           | 39                          |                           |          |
| LUSC                     | 8            | 70                          |                           |          |
| IV                       | 32           | 12 (37.5)                   | 20 (62.5)                 | 0.455    |
| LUAD                     | 11           | 14                          |                           |          |
| LUSC                     | 1            | 6                           |                           |          |

Data were extracted from the Human Protein Atlas (HPA, https://www.proteinatlas.org). Patients with MUC22<sup>Low</sup> or MUC22<sup>High</sup> tumors at different stages were classified based on the cutoff value of 0.02 shown in the HPA. <sup>a</sup>P<0.05 and <sup>b</sup>P<0.001 (χ² tests). MUC22, mucin 22; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.